Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty